BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,092 filers reported holding BAXTER INTL INC in Q1 2020. The put-call ratio across all filers is 0.81 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $2,033,000 | -18.9% | 25,037 | -16.4% | 0.20% | +42.4% |
| Q4 2019 | $2,506,000 | -61.2% | 29,963 | -59.4% | 0.14% | -53.1% |
| Q3 2019 | $6,463,000 | +19.9% | 73,887 | +12.2% | 0.31% | +27.9% |
| Q2 2019 | $5,391,000 | -28.9% | 65,827 | -29.4% | 0.24% | -18.1% |
| Q1 2019 | $7,580,000 | +11.0% | 93,219 | -10.1% | 0.29% | +6.2% |
| Q4 2018 | $6,829,000 | -33.3% | 103,749 | -21.8% | 0.28% | -8.3% |
| Q3 2018 | $10,231,000 | +0.6% | 132,719 | -3.6% | 0.30% | -3.5% |
| Q2 2018 | $10,168,000 | +17.9% | 137,699 | +3.9% | 0.31% | +13.5% |
| Q1 2018 | $8,622,000 | -63.1% | 132,557 | -63.3% | 0.28% | -61.4% |
| Q4 2017 | $23,342,000 | +0.2% | 361,103 | -2.8% | 0.71% | -3.4% |
| Q3 2017 | $23,305,000 | -30.4% | 371,388 | -32.9% | 0.74% | -18.5% |
| Q2 2017 | $33,507,000 | +12.1% | 553,465 | -4.0% | 0.90% | +5.4% |
| Q1 2017 | $29,895,000 | -17.2% | 576,450 | -29.2% | 0.86% | -10.6% |
| Q4 2016 | $36,123,000 | -2.4% | 814,682 | +4.7% | 0.96% | -6.2% |
| Q3 2016 | $37,026,000 | +8.5% | 777,862 | +3.1% | 1.02% | +2.9% |
| Q2 2016 | $34,114,000 | +317.4% | 754,402 | +279.2% | 1.00% | +316.3% |
| Q1 2016 | $8,172,000 | – | 198,930 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |